參考資料：Mindell Jodi A, Owens Judith A, A Clinical Guide to Pediatric Sleep (Diagnosis and Management of Sleep Problems), Lippincott Williams & Wilkins 2003
資料來源： 1. Strausz S, Kiiskinen T, Broberg M, et al. Sleep apnoea is a risk factor for severe COVID-19. BMJ Open Respir Res. 2021;8(1):e000845. doi:10.1136/bmjresp-2020-000845
2.Gill CM, Piggott LM, Kent BD. Sleep medicine and coronavirus disease 2019. Curr Opin Pulm Med. 2021;27(6):529-534. doi:10.1097/MCP.0000000000000822
test test test test test test test test test test test test test test test test test test test test test v test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test
test test test test test test test test test test test test test test test test test test test test test v test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test
test test test test test test test test test test test test test test test test test test test test test v test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test
test test test test test test test test test test test test test test test test test test test test test v test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test
test test test test test test test test test test test test test test test test test test test test test v test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test
The 30th Taiwan Excellence Award recently announced the winners from a long list of candidates. Somnics, Inc. won its third Taiwan Excellence Award for the new generation iNAP Oral Interface I08, an accessory for the OSA (obstructive sleep apnea) treatment device iNAP Sleep Therapy System. This is the acknowledgment of the company’s R&D and manufacturing capability and the encouragement for continued innovation to meet the market’s unmet needs.
The Taiwan Excellence Award, organized by the Bureau of Foreign Trade and operated by Taiwan External Trade Development Council (TAITRA), is an important event that celebrates Taiwanese companies’ achievement in product development and production. This award has established international credibility with over 100 judges from Taiwan and overseas screening and selecting winners based on R&D, design, quality, marketing and local manufactured in Taiwan. In its 30th year in 2021, Taiwan Excellence issued its third award to Somnics, Inc. On this occasion, the Oral Interface I08, an accessory of iNAP, stood out from the crowd.
The iNAP One Sleep Therapy utilizes intraoral negative air pressure to treat OSA patients. The iNAP creates a gentle oral vacuum to stabilize the tongue and soft tissues and free the airway. Unlike the traditional CPAP, the iNAP lets a patient breathe normally through the nose during sleep without a mask and blowing air. iNAP has a soft, flexible oral interface that users wear during sleep, which gives excellent wearing comfort compared to a CPAP facial mask. The oral interface has to be used throughout the sleep and is the key to whether the patient can adopt the negative pressure treatment for the long term. This seemingly simple design is the achievement after years of development.
The new generation iNAP Oral Interface, I08, improves the fitting and fixation by advanced pressure distribution and adjustable parts. The I08 comprises with three modularized parts: a Lip Shield, a Tongue Shield, and a Flexible Plate with different sizes. Users can select the proper size from 80 combinations according to the physician's evaluation and personalize their own oral interface that is most comfortable, best secured and has better therapeutic effects. Most of the Taiwan Excellence Award winners this year are the optimal solutions developed to address users’ needs and experience, accompanied by new and smart business models and services for consumers. Somnics Inc.’s iNAP new generation Oral Interface I08, since its debuts with European Product Design Award in 2019, has been certified in Europe (CE Marking) in 2020 and Taiwan (TFDA) in 2021. For the first launched set, a total of 9 combinations are available to meet the needs of 80% of the OSA patients, who can personalize their treatment.
Taiwan Excellence issued its third award to Somnics for the Oral Interface I08, an accessory of iNAP.
而東協睡眠聯盟主席Dương Qúy Sỹ醫師在2018年一場於范玉石醫科大學(Pham Ngoc Thach University of Medicine)的睡眠醫學研討會上指出，越南，這個2020年東協前三大醫材市場，「恐怕有不下於80萬名民眾正遭遇阻塞型睡眠呼吸中止症問題」。這也意味者，越南對於睡眠呼吸治療也有著相當大的潛在需求…這也讓萊鎂醫更有信心從越南出發推廣iNAP® One負壓睡眠呼吸治療裝置，讓正在尋求克服阻塞型睡眠呼吸中止症(OSA)的越南與其他SEA地區民眾，有機會接觸此一已證明嶄新又有效的解決方案。
萊鎂醫療器材已於2021年5月通過南韓食品醫藥品安全處(Ministry of Food and Drug Safety, MFDS)境外查廠評鑑GMP核可，預計今年第三季將取得iNAP負壓睡眠呼吸治療裝置產品認證，攜手韓國LMT Korea Co., Ltd進軍韓國市場，造福當地阻塞型呼吸中止症(OSA)患者。
萊鎂醫表示，公司已於2020年與位於京畿道的韓國LMT Korea Co., Ltd簽訂合作合約，於韓國醫療器材取證後在當地推廣iNAP負壓睡眠呼吸治療裝置與服務。LMT Korea是南韓最主要的睡眠呼吸診斷與治療裝備商之一，同時是德國Lowenstein呼吸器獨家代理商，服務體系完整，與超過200家醫療機構合作密切，擁有韓國CPAP呼吸機最大市占率；該公司並建置有南韓唯一的睡眠訓練中心LÖWENSTEIN Academy進行睡眠專家培訓。萊鎂醫與LMT Korea基於共同的意念“患者值得擁有更好的OSA治療體驗”而攜手合作。
